Medical bottles and syringes are seen with the logo of the new Nordisk shown on the screen in the background.
Nurphoto | Nurphoto | Getty Images
Novo NordiskHopes that they will announce a new era of treatment with obesity with their cure Cagrisem have been called into question after a number of experimental results have sent stakes.
The title is the result of redefin-2 trials in the late phase released Earlier this month, he showed that Novo’s new generation Cagrisem helped obese or excessive adult patients with type 2 diabetes, lost 15.7% of his weight for 68 weeks, compared to 3.1% with placebo. This was below the percentage of high teenagers earlier forecasts.
Previous trial in late phase published In December, he showed that the drug was helped by obese or overweight with one or more chamberbits, but not by type 2 diabetes, reducing their weight by 22.7% after 68 weeks, also below the expected 25%.
Both results have wiped out significant value from the new share price, as investors are in hope that they will find a superior alternative to the existing injection of the company and rival Eli Lily’s Zebownovo, both of the GLP-1 drug, were intricate.
Formerly a dear section now dropped about 50% of its 2024 highlights.
“The feeling of these guys is just as negative as always,” said Emily Field, a European research leader of pharmaceutical products in Barclays, said on Wednesday for CNBC over the phone on Wednesday.
Novo Nordisk
“The reaction of the stock was disproportionate, but there are simply no customers who make up for the sellers,” Field said, noting that some US HEDGE funds have now adorned supplies, either because of the results of the experiments or because of the wider concern due to high assessment of weight loss drugs.
Obesity treatment of the next gene
Cagrisema is a combination of cagrilintida – a working shape of weight loss treatment known as analog Amilin – and semaglutide, an active ingredient in Wegovy.
It hoped that the drug would offer improved weight loss for patients with diabetes, which usually have a heavier rejection time of pounds on existing GLP-1 treatments, but a decrease in weight of 15.7% is the result of disappointment of redefine-2 experiments.
“We saw the potential for Cagrisem to show a superior weight loss from Zepbound with respect to the amilin component; however, Delta Cagrisem from obese to obese patients with diabetics looks very similar to SEMA and ZEPBOUND,” said Bofa Global Research in the notes in the past week, adding that the results are not sufficient.
It is currently a very, very short -term focus. People just don’t think about wider potential.
Emily Field
Head of European Pharmaceutical Product Research at Barclays
In the meantime, there are questions about Cagrisem tolerance, with less than two -thirds of patients who have progressed at the highest dose after 68 weeks. The new one said last week that Cagrisema was “well -tolerated” and that the most common harmful effects were gastrointestinal, but they were “mild to moderate and reduced” over time.
“Investors are looking for treatment options that are best in the class and will provide a new place in the Obesity Market,” Soren Lontoft, analyst Pharma Equity from Sydbank, told CNBC on Tuesday. “We are not sure that Cagrisema is the best in the class.”
However, the upcoming redefine-4 study, which should be published at the beginning of 2026, could provide the further color of the efficiency of the drug over a long duration and flexible dosage-notes that Lontoft said it could single out.
“That could bring superiority,” Lontoft said.
Expanding treatment for weight loss
The weight loss industry remains divided by the wider administration and the results of the drug for obesity after the total weight decrease. In a separate note last week, Bofa said that she became “a little more careful about distinguishing” in the treatment of obesity and diabetes after the latest results of Cagrisem.
“There is a very, very short -term focus at the moment. People just don’t think about wider potential,” Field remarked.
Lontoft, however, pointed out the need for a variety of treatments for solving and obesity and associated health risks, such as cardiovascular diseases, apnea apnea and liver disease – areas where medicines have already proven to be moving forward.
“It’s about solving different needs in this market,” he said. “Companies that are able to resolve these different needs of the best will – in combination with significant production capacities – to take over the most of this market,” he said.
Other companies hope to get involved in the market, which is estimated to be worth more than $ 100 billion by 2030. Earlier this month, the Swiss pharmaceutical giant Roche achieved a job worth up to $ 5.3 billion for the development of Danish biotechnics Zealand’s farmwith Analog Amilin Candidate for Obesity Medicines.
Investors and patients will have to wait sometime for such products to be launched, however, with executive director and President Adam Stoensberg in Zealand Pharma narrates CNBC that he expects to come to the market around 2030. The new Nordisk, meanwhile, said he was expecting to apply for a regulatory approval for Cagrisema in the first quarter of 2026.
Still, the company has some way to make up for some earlier hype around the drug. When asked if investors would recognize him as one of several possible alternatives to the existing heavy weights, Soren was careful: “No. But I think he will do in the end.”
